Key result
Recombinant human IGF-1 improves insulin sensitivity and offers potential vascular protection in chronic heart failure.
IGF-1 is a peptide hormone that is expressed in most tissues. It shares significant structural and functional similarities with insulin, and is implicated in the pathogenesis of insulin resistance and cardiovascular disease. Recombinant human IGF-1 has been used in Type 2 diabetes to improve insulin sensitivity and aid glycemic control. There is evidence supporting IGF-1 as a vascular protective factor and it may also be beneficial in the treatment of chronic heart failure. Further understanding of the effects of IGF-1 signaling in health and disease may lead to novel approaches to the prevention and treatment of diabetes and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2008) conducted a review in Type 2 diabetes and cardiovascular disease. IGF-1 was evaluated. Recombinant human IGF-1 improves insulin sensitivity in Type 2 diabetes and may act as a vascular protective factor beneficial in the treatment of chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: